PT1221950E - Combinacoes sinergicas de um antagonista do receptor de nk1 e de um analogo estrutural de gaba - Google Patents

Combinacoes sinergicas de um antagonista do receptor de nk1 e de um analogo estrutural de gaba

Info

Publication number
PT1221950E
PT1221950E PT00966138T PT00966138T PT1221950E PT 1221950 E PT1221950 E PT 1221950E PT 00966138 T PT00966138 T PT 00966138T PT 00966138 T PT00966138 T PT 00966138T PT 1221950 E PT1221950 E PT 1221950E
Authority
PT
Portugal
Prior art keywords
synergistic combinations
structural analogue
gaba
receiver antagonist
antagonist
Prior art date
Application number
PT00966138T
Other languages
English (en)
Inventor
John Hughes
Lakhbir Singh
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PT1221950E publication Critical patent/PT1221950E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT00966138T 1999-10-07 2000-10-05 Combinacoes sinergicas de um antagonista do receptor de nk1 e de um analogo estrutural de gaba PT1221950E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15827199P 1999-10-07 1999-10-07

Publications (1)

Publication Number Publication Date
PT1221950E true PT1221950E (pt) 2004-08-31

Family

ID=22567369

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00966138T PT1221950E (pt) 1999-10-07 2000-10-05 Combinacoes sinergicas de um antagonista do receptor de nk1 e de um analogo estrutural de gaba

Country Status (38)

Country Link
EP (2) EP1221950B1 (pt)
JP (2) JP2003510356A (pt)
KR (1) KR20020060192A (pt)
CN (1) CN1387434A (pt)
AP (1) AP2002002501A0 (pt)
AR (1) AR029646A1 (pt)
AT (1) ATE269072T1 (pt)
AU (2) AU7663300A (pt)
BG (1) BG106548A (pt)
BR (1) BR0014598A (pt)
CA (1) CA2385930A1 (pt)
CO (1) CO5280195A1 (pt)
CR (1) CR6614A (pt)
CZ (1) CZ20021116A3 (pt)
DE (1) DE60011650T2 (pt)
DK (1) DK1221950T3 (pt)
EA (1) EA004266B1 (pt)
EE (1) EE200200185A (pt)
ES (1) ES2220542T3 (pt)
GT (1) GT200000166A (pt)
HR (1) HRP20020286A2 (pt)
HU (1) HUP0203466A3 (pt)
IL (1) IL148965A0 (pt)
IS (1) IS6318A (pt)
MA (1) MA26826A1 (pt)
MX (1) MXPA02003484A (pt)
NO (1) NO20021625D0 (pt)
NZ (1) NZ517949A (pt)
OA (1) OA12063A (pt)
PA (1) PA8504301A1 (pt)
PE (1) PE20010708A1 (pt)
PL (1) PL357498A1 (pt)
PT (1) PT1221950E (pt)
SK (1) SK4542002A3 (pt)
TR (1) TR200200913T2 (pt)
UY (1) UY26376A1 (pt)
WO (2) WO2001024792A1 (pt)
ZA (1) ZA200202675B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL189872B1 (pl) 1996-07-24 2005-10-31 Warner Lambert Co Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
CN1662231A (zh) * 2002-04-24 2005-08-31 柏树生物科学公司 包括应激相关障碍在内的功能性躯体障碍的预防与治疗
CN1720025A (zh) * 2002-10-08 2006-01-11 兰贝克赛实验室有限公司 加巴喷丁片剂及其制备
AU2004224322A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators
WO2004084881A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS
US20060264509A1 (en) * 2003-03-21 2006-11-23 Fraser Matthew O Methods for treating pain using smooth muscle modulators and a2 subunit calcium channel modulators
EP1543831A1 (en) * 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Pregabalin composition
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
CA2805371C (en) 2010-07-30 2017-10-31 Toray Industries, Inc. Therapeutic agent or prophylactic agent for neuropathic pain
DK2621282T3 (da) * 2010-09-28 2020-05-04 Univ California Gaba-agonister i behandlingen af forstyrrelser forbundet med metabolisk syndrom og gaba-kombinationer i behandling eller profylakse af type i diabetes
DK3946260T3 (da) * 2019-03-26 2026-03-23 Orion Corp Pregabalinformuleringer og anvendelse deraf
WO2022234110A1 (en) * 2021-05-07 2022-11-10 Plus Vitech, S.L. Gamma-aminobutyric acid derivatives for use in cancer therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
US5510381A (en) * 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
DE69736390T2 (de) * 1996-10-07 2007-07-26 Merck Sharp & Dohme Ltd., Hoddesdon Zns-penetrierende nk-1 rezeptorantagonisten als antidepressivum und / oder anxiolytikum
JP2001504848A (ja) * 1996-12-02 2001-04-10 メルク シヤープ エンド ドーム リミテツド 重症不安障害の治療のためのｎｋ−１受容体拮抗薬の使用

Also Published As

Publication number Publication date
IL148965A0 (en) 2002-11-10
HUP0203466A2 (hu) 2003-02-28
AR029646A1 (es) 2003-07-10
HRP20020286A2 (en) 2003-08-31
BR0014598A (pt) 2002-06-11
WO2001024792A1 (en) 2001-04-12
DE60011650T2 (de) 2005-07-14
GT200000166A (es) 2002-03-30
MXPA02003484A (es) 2004-09-10
CA2385930A1 (en) 2001-04-12
HUP0203466A3 (en) 2005-03-29
PE20010708A1 (es) 2001-07-27
AP2002002501A0 (en) 2002-06-30
DK1221950T3 (da) 2004-09-20
OA12063A (en) 2006-05-03
CO5280195A1 (es) 2003-05-30
EP1233766A1 (en) 2002-08-28
WO2001024792A9 (en) 2002-09-06
SK4542002A3 (en) 2003-09-11
EP1221950B1 (en) 2004-06-16
BG106548A (en) 2002-12-29
UY26376A1 (es) 2000-12-29
MA26826A1 (fr) 2004-12-20
JP2003510355A (ja) 2003-03-18
KR20020060192A (ko) 2002-07-16
WO2001024791A1 (en) 2001-04-12
EP1221950A1 (en) 2002-07-17
CZ20021116A3 (cs) 2003-05-14
NO20021625L (no) 2002-04-05
NO20021625D0 (no) 2002-04-05
PA8504301A1 (es) 2002-08-26
JP2003510356A (ja) 2003-03-18
ATE269072T1 (de) 2004-07-15
NZ517949A (en) 2003-08-29
CN1387434A (zh) 2002-12-25
CR6614A (es) 2003-12-04
PL357498A1 (en) 2004-07-26
AU7663300A (en) 2001-05-10
IS6318A (is) 2002-03-21
EA004266B1 (ru) 2004-02-26
TR200200913T2 (tr) 2002-09-23
DE60011650D1 (de) 2004-07-22
EA200200303A1 (ru) 2002-08-29
EE200200185A (et) 2003-04-15
ZA200202675B (en) 2003-04-15
AU1696201A (en) 2001-05-10
ES2220542T3 (es) 2004-12-16

Similar Documents

Publication Publication Date Title
PT1221950E (pt) Combinacoes sinergicas de um antagonista do receptor de nk1 e de um analogo estrutural de gaba
AU7061901A (en) N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives
MA26762A1 (fr) Derives de pyrrolidine- antagonistes du recepteur ccr-3
EP1144004A4 (en) HER-2 BINDING ANAGONISTS
BR9612327A (pt) Antagonistas receptores de vitronectina
BR9612378A (pt) Antagonistas receptores de vitronectina
CY2010003I1 (el) Αγωνιστες των βητα-2 αδρενεργικων υποδοχεων
BR9704071A (pt) Derivados de imino como inibidores de ressorção de ossos e antagonistas de receptores vitronectina
EP0810994A4 (en) FIBRINOGEN RECEPTOR ANTAGONISTS
PT856001E (pt) Derivados de pirimidina enquanto antagonistas do receptor 5ht2c
SI1379647T1 (sl) Antagonist antiteles sesaläśevega citokina ali njegovega receptorja za zdravljenje alergije
DE60036093D1 (de) Antagonisten des gardos-kanals
DK0923550T3 (da) Acylaminoalkylen-amid-derivater som NK1- og NK2-antagonister
FR2790946B1 (fr) Injecteur de greffons osseux
ITMI940039A0 (it) Associazione dotata di effetto sinergico che ha un effetto antagonista dei recettori nk1 e nk2
AU3958902A (en) Crf receptor antagonists and methods relating thereto
IL154358A0 (en) Treatment of hiv-1 infection and inflammatory disease using cyclophilin receptor antagonists
BR9609914A (pt) Antagonista do receptor de endotelina
BR9606668A (pt) Piridazinonas como antagonista de receptor-endotelina
ATE290546T1 (de) Tachykinin antagoniste
NO20021113D0 (no) Vitronectin-reseptor-antagonister
BR9603432A (pt) Antagonistas de receptores de endotelina
FI941118L (fi) Bentsyyli-imidatsopyridiinijohdannainen angiotensiini II reseptoriantagonistina
DK1173172T3 (da) Synergistiske virkninger af amlodipin og den hydroxylerede metabolit af atorvastatin
ZA981206B (en) Use of NMDA receptor antagonist